Zimmer Biomet Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting net sales of $2,062.9 million and net earnings attributable to the company of $191.6 million for the third quarter.

Key Highlights

  • Q3 2026 Net Sales: $2,062.9 million, compared with $2,001.4 million in Q3 2025, according to the filing.
  • Q3 2026 Net Earnings (Zimmer Biomet): $191.6 million, or $1.00 per diluted share, versus $230.9 million, or $1.16 per diluted share, in Q3 2025.
  • Nine-Month Net Sales: $6,326.6 million for the nine months ended September 30, 2026, compared with $5,987.7 million for the same period in 2025.
  • Share Repurchases: The company repurchased 6.3 million shares for $585.2 million in the nine months ended September 30, 2026, the filing disclosed.
  • Dividends Declared: Cash dividends of $0.72 per share were declared in the nine-month period, including $0.24 per share in Q3 2026.
  • Total Assets: $23,538.6 million as of September 30, 2026, up from $23,091.7 million at December 31, 2025.
  • Shares Outstanding: 189,253,888 shares of common stock were outstanding as of October 30, 2026, per the filing.

Zimmer Biomet's Third-Quarter and Year-to-Date Financial Results Through September 30, 2026

According to the filing, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported net sales of $2,062.9 million for the three months ended September 30, 2026, an increase from $2,001.4 million in the comparable prior-year quarter. Operating profit for Q3 2026 was $307.6 million, compared with $351.3 million in Q3 2025. The company reported earnings before income taxes of $230.1 million for the quarter, with a provision for income taxes of $37.2 million, resulting in net earnings attributable to Zimmer Biomet of $191.6 million, or $1.00 per diluted share.

For the nine months ended September 30, 2026, the filing reported net sales of $6,326.6 million and net earnings attributable to Zimmer Biomet of $628.1 million, or $3.25 per diluted share. This compares with net sales of $5,987.7 million and net earnings of $565.8 million, or $2.84 per diluted share, for the same nine-month period in 2025. Operating profit for the nine-month period was $1,006.8 million versus $943.6 million a year earlier. Interest expense, net, was $216.6 million for the nine months ended September 30, 2026, compared with $220.9 million for the same period of 2025.

The condensed consolidated balance sheet as of September 30, 2026, reflected total assets of $23,538.6 million and total liabilities of $10,813.0 million. Long-term debt stood at $6,216.5 million, down from $6,932.0 million at December 31, 2025, while the current portion of long-term debt increased to $1,287.7 million from $587.1 million over the same period. Treasury stock totaled $9,474.3 million, reflecting 129.5 million shares repurchased as of September 30, 2026, compared with 123.2 million shares at December 31, 2025. Total stockholders' equity was $12,725.6 million.

What Was Disclosed

Zimmer Biomet filed its quarterly report covering the three and nine months ended September 30, 2026, disclosing income statement results, balance sheet positions, stockholders' equity activity including $585.2 million in share repurchases, and cash dividends of $0.72 per share declared year-to-date.